The Department of Health and Human Services (HHS) Office of Inspector General (OIG) has issued a comprehensive report highlighting critical vulnerabilities within the Medicare Advantage (MA) program, specifically regarding the oversight and screening of Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) providers. According to the federal watchdog, the Centers for Medicare & Medicaid Services (CMS) and private Medicare Advantage organizations (MAOs) are failing to implement sufficiently rigorous screening protocols, leaving the door open for billions of dollars in fraudulent billing. The report specifically identifies out-of-network providers—many of whom are not enrolled in the traditional Medicare program—as the primary source of risk, noting that these entities often bypass the stringent accreditation and licensure checks required of their in-network counterparts.
The Growing Crisis of DMEPOS Fraud in Medicare
Fraud related to DMEPOS has remained a persistent and costly thorn in the side of the federal government for decades. These supplies, which range from basic crutches and oxygen tanks to high-tech robotic prosthetics and complex orthotic braces, represent a massive sector of healthcare spending. Because these items are frequently prescribed and easily shipped, they have become a favored vehicle for bad actors seeking to exploit the reimbursement system. The OIG notes that as enrollment in Medicare Advantage continues to surge—now surpassing enrollment in traditional fee-for-service Medicare—the financial stakes have never been higher.
The nature of DMEPOS fraud often involves "telemarketing" schemes where seniors are contacted via phone and offered "free" or "low-cost" medical braces or equipment. Once the scammers obtain the beneficiary’s Medicare number, they bill the government for expensive equipment that is either medically unnecessary, never delivered, or of significantly lower quality than what was billed. The OIG’s latest investigation suggests that the transition of beneficiaries to private MA plans has not insulated the program from these tactics; rather, it may have created new loopholes for exploitation.
Comparative Data: The Out-of-Network Disparity
One of the most striking findings in the OIG’s recent investigation is the massive disparity in billing amounts between providers who are enrolled in the traditional Medicare program and those who operate exclusively as out-of-network providers for MA organizations. The OIG conducted an in-depth analysis of six major MA organizations that collectively manage more than 21,000 DMEPOS suppliers. Of these, nearly 8,000—approximately 38%—were classified as out-of-network.
The financial data revealed a staggering gap: while the average monthly billing for orthotics supplies among Medicare-enrolled suppliers was approximately $210 per beneficiary, the monthly amount billed by out-of-network suppliers for identical categories of supplies averaged $1,399. This represents a nearly seven-fold increase in costs for the same medical goods. When interviewed by federal investigators, two of the MA organizations admitted that out-of-network providers were responsible for "nearly all" of the identified fraud schemes within their networks.
This data suggests that out-of-network providers may be utilizing the lack of oversight to submit highly inflated claims. Because these providers do not have a direct contractual relationship with the MAO and are not subject to the same pre-service vetting as in-network providers, they often fly under the radar until significant financial damage has already occurred.
Regulatory Loopholes and the Enrollment Gap
A central issue identified by the OIG is the "enrollment gap" between traditional Medicare and Medicare Advantage. In the original Medicare program, any supplier wishing to bill the government must be officially enrolled. This enrollment process is rigorous, requiring suppliers to meet specific quality standards, obtain accreditation, and verify state licensure.
However, current federal regulations do not mandate that a DMEPOS provider be enrolled in the traditional Medicare program to provide services to a Medicare Advantage member. While MA organizations are encouraged to screen their providers, they are legally prohibited from requiring Medicare enrollment as a condition for out-of-network reimbursement. This creates a regulatory "blind spot" where providers who have been banned from traditional Medicare—or those who would never pass the initial screening—can still receive payments through private MA plans.
The OIG report found that MA organizations were particularly lax in verifying whether out-of-network suppliers met state-level licensing requirements or held proper accreditation. In many cases, the only check performed was a retroactive review after a claim had already been flagged for suspicious activity.
The Failure of the CMS Preclusion List
The OIG also directed significant criticism toward CMS for its management of the "Preclusion List." This list is intended to be a vital screening tool, containing the names of providers and suppliers who have had their Medicare enrollment revoked for cause or who have been barred from the program due to fraudulent activity. Under federal guidelines, MA organizations are supposed to use this list to deny payment to bad actors.
However, the OIG found that CMS primarily uses the Preclusion List retroactively. Instead of serving as a "front-door" preventative measure to keep fraudulent suppliers out of the system entirely, the list is often updated only after a provider has already successfully bilmed the program for months or years. Furthermore, the OIG accused CMS of failing to ensure that MA organizations were checking the list consistently for out-of-network claims. The report argues that by the time a supplier appears on the Preclusion List, the fraudulent funds have often already been moved or spent, making recovery nearly impossible.
A Chronology of Reform and Fraud Crackdowns
The current OIG report is part of a broader, multi-year effort by the federal government to rein in medical equipment fraud. The timeline of these efforts shows a fluctuating level of intensity in regulatory oversight:
- 2015–2017: A previous OIG audit discovered that Medicare improperly paid DMEPOS suppliers over $34 million for equipment provided to beneficiaries who were actually in inpatient stays (where the hospital is responsible for the cost). This highlighted systemic failures in claim-processing logic.
- 2018: The Trump administration launched a significant crackdown on DMEPOS fraud. This included "Operation Brace Yourself," a multi-agency effort that targeted a $1.2 billion international scam involving orthopedic braces.
- 2019: CMS imposed a rare six-month moratorium on the enrollment of new DMEPOS suppliers in certain high-risk geographic areas, including parts of Florida and California, to allow investigators time to vet existing providers.
- 2020–2024: As Medicare Advantage enrollment soared to over 50% of the total Medicare population, oversight focus shifted toward the private plans. During this period, the OIG began noticing that while traditional Medicare fraud was being squeezed, the volume of suspicious claims in MA was rising.
- 2025: CMS announced that its enhanced data modeling and AI-driven screening tools stopped more than $1.5 billion in suspected fraudulent billing by medical supply companies in a single fiscal year. Despite this success, the OIG’s latest report suggests that billions more remain at risk due to the specific loopholes in MA out-of-network billing.
Recommendations for Systemic Change
In light of these findings, the OIG has issued several urgent recommendations to CMS and Medicare Advantage organizations. The primary goal is to harmonize the screening requirements between traditional Medicare and MA to ensure that there is "no wrong door" for fraud.
- Mandatory Medicare Enrollment: The OIG recommends that CMS seek legislative or regulatory changes to require that all DMEPOS suppliers who bill Medicare Advantage—including out-of-network providers—be enrolled in the traditional Medicare program. This would subject them to the same "Gold Standard" of vetting.
- Proactive Use of the Preclusion List: CMS should transition the Preclusion List from a retroactive enforcement tool to a proactive screening requirement. MAOs should be required to verify every supplier against the list before any payment is authorized.
- Enhanced Monitoring of Out-of-Network Claims: MA organizations must implement more aggressive real-time monitoring of out-of-network billing patterns. The OIG suggests that any out-of-network claim for orthotics that exceeds the traditional Medicare average by a certain percentage should trigger an automatic manual review.
- Verification of Licensure and Accreditation: MAOs must be held accountable for ensuring that out-of-network suppliers meet the same state-specific legal requirements as in-network providers.
According to the report, CMS has concurred with the OIG’s recommendations or has pledged to take them into consideration for future rulemaking. However, implementing these changes may face pushback from insurance industry lobbyists who argue that overly burdensome screening requirements could delay the delivery of necessary medical equipment to seniors.
Analysis of Implications for Taxpayers and Beneficiaries
The implications of this report extend far beyond administrative paperwork. For taxpayers, the $1.5 billion in stopped fraud in 2025 is likely only the tip of the iceberg. As the Medicare Trust Fund faces long-term solvency challenges, the loss of billions to fraudulent medical equipment schemes accelerates the timeline toward a potential funding crisis.
For beneficiaries, the risks are more personal. When a fraudulent supplier bills for a "back brace" that a senior never requested, it can "lock" that beneficiary’s record. If that senior later has a legitimate medical need for a brace, Medicare may deny the claim, stating that the "benefit has already been used." Furthermore, the lack of screening for out-of-network providers means that seniors may receive sub-standard or even dangerous medical equipment that has not been vetted for safety or efficacy.
The OIG’s report serves as a stark reminder that as the healthcare system becomes more privatized through programs like Medicare Advantage, federal oversight must evolve to keep pace. The "seven-times-higher" billing figure for out-of-network orthotics is not just a statistical anomaly; it is a clear indicator of a system that is being systematically exploited. Without the swift implementation of the OIG’s recommendations, the Medicare Advantage program remains a high-value target for those looking to turn a profit at the expense of the American taxpayer and the nation’s most vulnerable citizens.
